This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stanley, S. L. Search for Related Content PubMed PubMed Citation Articles by Stanley, S. L., Jr

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, Oct 1997, 637-649, Vol 10, No. 4
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Progress towards development of a vaccine for amebiasis

SL Stanley Jr
Department of Medicine and Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. sstanley@im.wustl.edu

The application of molecular biologic techniques over the past decade has seen a tremendous growth in our knowledge of the biology of Entamoeba histolytica, the causative agent of amebic dysentery and amebic liver abscess. This approach has also led to the identification and structural characterization of three amebic antigens, the serine- rich Entamoeba histolytica protein (SREHP), the 170-kDa subunit of the Gal/GalNAc binding lectin, and the 29-kDa cysteine-rich protein, which all show promise as recombinant antigen-based vaccines to prevent amebiasis. In recent studies, an immunogenic dodecapeptide derived from the SREHP molecule has been genetically fused to the B subunit of cholera toxin, to create a recombinant protein capable of inducing both antiamebic and anti-cholera toxin antibodies when administered by the oral route. Continued progress in this area will bring us closer to the goal of a cost-effective oral combination "enteric pathogen" vaccine, capable of inducing protective mucosal immune responses to several clinically important enteric diseases, including amebiasis.

This article has been cited by other articles:

• Ivory, C. P. A., Chadee, K. (2007). Intranasal Immunization with Gal-Inhibitable Lectin plus an Adjuvant of CpG Oligodeoxynucleotides Protects against Entamoeba histolytica Challenge. Infect. Immun. 75: 4917-4922 [Abstract] [Full Text]  
• Haghighi, A., Kobayashi, S., Takeuchi, T., Thammapalerd, N., Nozaki, T. (2003). Geographic Diversity among Genotypes of Entamoeba histolytica Field Isolates. J. Clin. Microbiol. 41: 3748-3756 [Abstract] [Full Text]  
• Upcroft, P., Upcroft, J. A. (2001). Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa. Clin. Microbiol. Rev. 14: 150-164 [Abstract] [Full Text]  
• Que, X., Reed, S. L. (2000). Cysteine Proteinases and the Pathogenesis of Amebiasis. Clin. Microbiol. Rev. 13: 196-206 [Abstract] [Full Text]